Skip to main
ANIX

ANIX Stock Forecast & Price Target

ANIX Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Anixa Biosciences presents a favorable outlook driven by significant advancements in its clinical programs, particularly the Phase 1 data from its breast cancer vaccine, which met primary endpoints and demonstrated immune responses in 74% of participants, along with promising survival signals from the CAR-T therapy lira-cel for ovarian cancer. The strategic targeting of the follicle-stimulating hormone receptor (FSHR) by lira-cel may enhance tumor selectivity while minimizing off-target toxicity, highlighting the potential competitive advantage of its approach in this niche therapeutic area. Furthermore, the upcoming presentation of lira-cel at a prominent oncology conference indicates ongoing clinical progress and heightened visibility within the medical community, supporting investor confidence in the company's future commercial prospects.

Bears say

Anixa Biosciences Inc. faces significant financial challenges, evidenced by limited revenue streams primarily stemming from its legacy operations in the Other segment and insufficient market traction for its developmental Cancer Vaccines and CAR-T Therapies. The company's reliance on early-stage therapies, which are subject to lengthy and costly clinical trials, heightens the risk of delayed commercialization and potential capital needs beyond current resources. Additionally, the competitive landscape in oncology and a lack of diversification in its product portfolio further exacerbate the uncertainties surrounding the company’s financial outlook.

ANIX has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Anixa Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Anixa Biosciences Inc (ANIX) Forecast

Analysts have given ANIX a Strong Buy based on their latest research and market trends.

According to 3 analysts, ANIX has a Strong Buy consensus rating as of Apr 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Anixa Biosciences Inc (ANIX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.